MET and neoplasm: Of note, two of the c-MET inhibitors evaluated in our study, crizotinib and tivantinib, are already used in the clinical setting for different tumor types [45] and a phase I trial of gemcitabine combined with tivantinib, which emerged as the most active compound in our 3D models, showed good tolerability and early signs of antitumor activity, warranting further development of this combination in several solid tumors, including PDAC [46].